Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Zoetis Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.66, while Zoetis Inc trades at $77 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EMB | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $156.76 |
52-Week Low | $91.59 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.
Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
